|Bid||0.00 x 4000|
|Ask||0.00 x 1200|
|Day's Range||10.91 - 11.61|
|52 Week Range||5.95 - 40.00|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 01, 2022 - Nov 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.30|
Subscribe to Yahoo Finance Plus to view Fair Value for ADPT
Joining the call today are Chad Robins, our CEO and co-founder; and Tycho Peterson, our chief financial officer. In addition, Harlan Robins, Adaptive's chief scientific officer and co-founder; Nitin Sood, head of the immune medicine -- of the MRD business; and Sharon Benzeno, head of immune medicine business, will be available for Q&A. With that, I'll turn the call to Chad Robins.
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 7.50% and 0.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SEATTLE, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended June 30, 2022. “We are pleased to deliver another strong quarter across both the MRD and Immune Medicine businesses,” said Chad Robins, chief executive officer